

Curriculum Vitae

Markus Weckmann

Professor, Dr. rer. nat. / Dipl.-Ing. (FH)
d.o.b. January 07, 1978, Munich, Germany

University Education

- 2022 Habilitation 'Experimental Pneumology', University of Lübeck
- 2008 PhD, Children's Hospital Freiburg, Max-Planck-Institute for Immuno-Biology and University of Freiburg, Germany
- 1998 – 2003 Study of Biotechnology, University of Applied Science Weihenstephan, Freising, Germany

Scientific Career

- Since 2022 Joint Professorship for Epigenetics in Pneumology (W2), between the University of Lübeck and the Leibniz Lung Research Center Borstel
- Since 2019 Member of the Planning Committee of the Respiratory Structure and Function Assembly, American Thoracic Society
- Since 2018 Chairman elect of the working group "Experimental Pneumology" at the Society for Pediatric Pneumology
- 2015 - 2018 Speaker of the Junior Research Cluster "Chrono-inflammation – circadian gating of neutrophil inflammation" (University of Lübeck)
- Since 2015 Deputy Head of Research, Department of Pediatric Pneumology and Allergology, University Children's Hospital Lübeck, Germany
- Since 2014 Principal Investigator in the German Center for Lung Research
- 2010 – 2015 Post-Doctoral Fellow, University Children's Hospital Lübeck, Germany
- 2007 – 2010 Post-Doctoral Fellow, CRC for Asthma and Airways, University of Sydney, Australia

Awards and Honours

- 2020 Johannes Wenner Award (German lung foundation & Society of Pediatric Pneumology)
- 2019 Best Scientific Poster Award (Disease Area Asthma, German Center for Lung Research)
- 2010 LAM Foundation Travel Award (American Thoracic Society)
- 2005 Hoffmann – La Roche Foundation Travel Award

Citation Record

Total citations: 980; h-index 18; since 2017: 16 (Google Scholar August 24th, 2022)

Top-10 selected Publications

Maison N, Omony J, Illi S, Thiele D, Skevaki C, Dittrich AM, Bahmer T, Rabe KF, **Weckmann M**, Happle C, Schaub B, Meier M, Foth S, Rietschel E, Renz H, Hansen G, Kopp MV, von Mutius E, Grychtol R; ALLIANCE Study Group. T-high asthma phenotypes across life span. **Eur Respir J**. 2022 Feb 24;2102288

Twisselmann N, Pagel J, Künstner A, **Weckmann M**, Hartz A, Glaser K, Hilgendorff A, Göpel W, Busch H, Herting E, Weinberg JB, Härtel C. Hyperoxia/Hypoxia Exposure Primes a Sustained Pro-Inflammatory Profile of Preterm Infant Macrophages Upon LPS Stimulation. **Frontiers Immunol**. 2021 Nov 18;12:762789.

Weckmann M, Bahmer T, Bülow Sand JM, Rank Rønnow S, Pech M, Vermeulen C, et al. COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy. **Eur Respir J**. European Respiratory Society; 2021 Jul 29.

Holz O, Waschki B, Watz H, Kirsten A, Abdo M, Pedersen F, **Weckmann M**, et al. Breath volatile organic compounds and inflammatory markers in adult asthma patients - negative results from the ALLIANCE cohort. **Eur Respir J**. European Respiratory Society; 2020 Oct 2;:2002127.

Vermeulen CJ, Xu C-J, Vonk JM, Hacken Ten NHT, Timens W, Heijink IH, ... **Weckmann M** et al. Differential DNA methylation in bronchial biopsies between persistent asthma and asthma in remission. **Eur Respir J**. European Respiratory Society; 2019 Nov 14;:1901280.

Zissler UM, Ulrich M, Jakwerth CA, Rothkirch S, Guerth F, **Weckmann M**, et al. Biomatrix for upper and lower airway biomarker in allergic asthma. **J Allergy Clin Immunol**. 2018 Aug 16.

Faiz A, **Weckmann M**, Tasena H, Vermeulen CJ, Van den Berge M, Hacken Ten NHT, et al. Profiling of healthy and asthmatic airway smooth muscle cells following interleukin-1 β treatment: a novel role for CCL20 in chronic mucus hypersecretion. **Eur Respir J**. European Respiratory Society; 2018 Aug;52(2):1800310.

Spengler D, Winoto-Morbach S, Kupsch S, Vock C, Blöchle K, Frank S, ... **Weckmann, M**, et al. Novel therapeutic roles for surfactant-inositols and -phosphatidylglycerols in a neonatal piglet ARDS model. A translational study. **Am J Physiol Lung Cell Mol Physiol**. American Physiological Society; 2017 Aug 31;:ajplung.00128.2017.

Burgess JK, Boustany S, Moir LM, **Weckmann M**, Lau JY, Grafton K, et al. Reduction of tumstatin in asthmatic airways contributes to angiogenesis, inflammation, and hyperresponsiveness. **Am J Respir Crit Care Med**. 2010 Jan 15;181(2):106–15.

Weckmann M, Collison A, Simpson JL, Kopp MV, Wark PAB, Smyth MJ, et al. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. **Nat Med**. 2007 Nov;13(11):1308–15.